-$0.73 Earnings Per Share Expected for BeyondSpring (BYSI) This Quarter

Wall Street brokerages expect that BeyondSpring (NASDAQ:BYSI) will report ($0.73) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for BeyondSpring’s earnings, with estimates ranging from ($0.73) to ($0.72). BeyondSpring posted earnings of ($2.66) per share in the same quarter last year, which would indicate a positive year over year growth rate of 72.6%. The business is scheduled to announce its next earnings results on Monday, May 28th.

According to Zacks, analysts expect that BeyondSpring will report full year earnings of ($2.80) per share for the current year, with EPS estimates ranging from ($2.92) to ($2.67). For the next financial year, analysts expect that the firm will post earnings of ($2.18) per share, with EPS estimates ranging from ($2.85) to ($1.51). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow BeyondSpring.

How to Become a New Pot Stock Millionaire

BeyondSpring (NASDAQ:BYSI) last posted its earnings results on Tuesday, April 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06).

A number of equities research analysts have issued reports on the company. Zacks Investment Research upgraded BeyondSpring from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Thursday, April 5th. HC Wainwright set a $60.00 price objective on BeyondSpring and gave the company a “buy” rating in a research report on Tuesday, April 3rd. Finally, Maxim Group set a $52.00 price objective on BeyondSpring and gave the company a “buy” rating in a research report on Tuesday, April 3rd. Five analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $49.60.

Shares of NASDAQ:BYSI remained flat at $$27.05 during mid-day trading on Friday. The company had a trading volume of 12,039 shares, compared to its average volume of 5,905. The stock has a market capitalization of $607.43 and a P/E ratio of -6.15. BeyondSpring has a 12 month low of $19.55 and a 12 month high of $48.49.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/04/15/0-73-earnings-per-share-expected-for-beyondspring-bysi-this-quarter.html.

BeyondSpring Company Profile

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply